Epic Update : Wockhardt

FDA import alert has potential revenue loss of USD 100 million annually
Can restore 80 percent of affected revenue within 9 months
USFDA in its inspection found some good manufacturing practice compliance issues
Have submitted remedial action plan to USFDA
Issues only at injectable manufacturing side
USFDA did not inspect solid dosage portion of plant
Alert – Company to hold concall with investors & analysts today at 12.30 pm, hosted by Macquarie Securities.